Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HEALIUS LIMITED Director's Dealing 2023

Dec 21, 2023

65058_rns_2023-12-21_dd69f2f9-a39a-43d0-8129-cc3a6f3a4f26.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity HEALIUS LIMITED
ABN 24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Charles Taylor
Date of last notice 20 December 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances givingrise to the relevant interest. As shown
Date of change 21 December 2023
No. of securities held prior tochange 50,000 Ordinary Shares32,900 NED Share Rights
Class Ordinary Shares
Number acquired 50,000
Number disposed N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand estimated valuation $1.49 per Ordinary Share
No. of securities held afterchange 100,000 Ordinary Shares32,900 NED Share Rights
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under On market purchase dividend reinvestment plan, participation in buyback

Part 2 – Change of director’s interests in contracts Not applicable

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where prior written N/A clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided?

Authorised by the Company Secretary.

Mary Weaver Company Secretary Date: 22 December 2023

  • See chapter 19 for defined terms.

Appendix

3Y

Page

2